Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 1289

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 9C
Chunk 1289
---
 average foreign exchange rate for each month of the year from oanda.com.

			(2) 
			
			The amounts shown in this column represent the aggregate grant date fair value of the restricted share units computed in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 718, not the actual amounts paid to or realized by the directors during the covered fiscal year. The assumptions used in determining grant date fair value of these awards are set forth in Note 7 to our audited consolidated financial statements for the year ended September 30, 2025 included in this Annual Report.

			(3) 

			As of September 30, 2025, (i) Ms. Chypyha and Mr. Marshall each held 11,000 RSUs, (ii) Mr. Liu held 3,669 RSUs, (iii) Mr. MacDonald and Mr. Sistilli each held 20,001 RSUs, (iv) Mr. Olson held 7,332 RSUs and Mr. Oakes held 11,532 RSUs.

			(4) 

			There were no share options grants in the year ended September 30, 2025. As of September 30, 2025, (i) Ms. Chypyha, Mr. Marshall and Dr. Olson each held 2,858 share options, (ii) Mr. MacDonald and Mr. Sistilli each held 11,773 share options, (iii) Mr. Oakes held 11,773 share options and (iv) Dr. Liu held no share options.

			(5) 

			Mr. Oakes was not nominated for re-election at our Annual Meeting that was held on May 28, 2025.

61

Narrative to Director Compensation Table

Non-Employee Director Compensation Policy

The Board adopted a compensation policy effective June 7, 2019 and amended it effective March 24, 2022. As compensation for their services on the Board, each non-executive Board member received annual remuneration as noted below and prorated during the effective periods. The Chief Executive Officer does not receive any additional compensation for his services on the Board.

From March 24, 2022 through September 30, 2024, each non-executive director received annual base remuneration of $35,000 and the Board Chair received annual remuneration of $65,000, inclusive of compensation for his